Despite significant progress in the field of clinical oncology in terms of diagnostic and treatment methods, the results of anticancer therapy are still not fully satisfactory, especially due to limited response and high toxicity. This has forced the need for further research to finding alternative ways to improve success rates in oncological treatment. A good solution to this problem in the context of rapidly obtaining an effective drug that works on multiple levels of cancer and is also safe is the global strategy of repurposing an existing drug. Research into other applications of an existing drug enables a precise assessment of its possible mechanisms of action and, consequently, the broadening of therapeutic indications. This strategy is also supported by the fact that most non-oncological drugs have pleiotropic effects, and most of the diseases for which they were originally intended are multifactorial, which in turn is a very desirable phenomenon due to the heterogeneous and multifaceted biology of cancer. In this review, we will mainly focus on the anticancer potential of H1 antihistamines, especially the new generation that were not originally intended for cancer therapy, to highlight the relevant signaling pathways and discuss the properties of these agents for their judicious use based on the characteristic features of cancer.
尽管临床肿瘤学在诊断和治疗方法方面取得了显著进展，但抗癌治疗的效果仍不尽如人意，这主要归因于治疗反应有限和毒性较高。因此，迫切需要进一步研究以寻找替代途径来提高肿瘤治疗的成功率。在快速获得一种能在多个层面作用于癌症且安全有效的药物的背景下，重新利用现有药物的全球策略为解决这一问题提供了良好方案。对现有药物其他应用的研究能够精确评估其可能的作用机制，从而拓宽治疗适应症。这一策略还得到以下事实的支持：大多数非肿瘤药物具有多效性，且其最初针对的疾病多为多因素所致，而癌症的异质性和多面性生物学特性使得这种多效性成为非常理想的现象。在本综述中，我们将主要关注H1抗组胺药的抗癌潜力，特别是那些最初并非用于癌症治疗的新一代药物，以突出相关的信号通路，并基于癌症的特征讨论这些药物的特性，以便合理使用。
肿瘤(癌症)患者之家